Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call

GlobeNewswire
10/26

CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2026 financial results on Thursday, November 5, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

The conference call can be accessed live over the phone by dialing 1-800-347-6865 or, for international callers, 1-203-518-9757, and referencing Conference ID: STARLING. A replay will be available approximately three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the replay is 11162885. The replay will be available until 11:59 p.m. (Eastern Time) on Thursday, November 19, 2026.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://investors.starlingoncology.com/.

About Starling Oncology, Inc.

Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.2 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, Starling Oncology is coordinating cancer care for the better. For more information visit www.starlingoncology.com. Please follow us on LinkedIn, X (formerly Twitter), or Bluesky.  

Contacts

Media

ICR Healthcare

StarlingPR@icrhealthcare.com

Investors

ICR Healthcare

StarlingIR@icrhealthcare.com


免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10